paclitaxel micellar + gemcitabine

A combination therapy consisting of micellar paclitaxel (a solvent-free nanoparticle formulation using polymeric micelles for improved solubility and reduced solvent-associated toxicity) and gemcitabine (a nucleoside analog cytotoxic agent) administered via intravenous infusion as a chemotherapy regimen, primarily under investigation and use for advanced and metastatic pancreatic cancer. The micellar paclitaxel formulation (e.g., GENEXOL-PM) aims to overcome neurotoxicity and hypersensitivity arising from traditional paclitaxel solvents; micelles deliver paclitaxel by encapsulation, enhancing tumor targeting and reducing systemic toxicity while gemcitabine inhibits DNA synthesis in dividing cells. The combination is well-tolerated and shows efficacy comparable to other albumin-bound paclitaxel regimens in clinical trials[2][3][5].

Brand names

Genexol-PM + Gemzar

Other names

paclitaxel polymeric micelle + gemcitabinepaclitaxel-loaded micelles + gemcitabinepolymeric micellar paclitaxel + gemcitabine